SYR-472 Open-label Study

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01751360

Enrollment

Registered

2012-12-18

Start date

2013-04-01

Completion date

2013-08-01

Last updated

2023-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

To evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.

Interventions

DRUGSYR-472

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

-1. The participant is judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator. 2\. The participant can sign and date a written, informed consent form prior to the initiation of any study procedures.

Exclusion criteria

-1. The participant has concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease . 2. The participant is assessed to be ineligible for the study by the investigator or subinvestigator.

Design outcomes

Primary

Measure	Time frame	Description
Blood Glucose	7 days	Blood Glucose

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026